Most material SEC filings — October 6, 2026

PT Danantara Energy International agreed to purchase 250,000 shares of Series A Convertible Preferred Stock at $1,000/share for $250 million total (dated October 6, 2026). The investment is approximately 109% of HighPeak's $228.3M market cap. Proceeds will refinance existing credit facilities and fund working capital. The purchaser receives one board seat nomination right (at ≥5% ownership assuming conversion), anti-dilution protections, information rights, and conversion features into common stock at $9.50/share.

Kairos Pharma announced interim Phase 2 efficacy data for ENV-105 (carotuximab) combined with apalutamide in metastatic castration-resistant prostate cancer. Median progression-free survival was 17.7 months with combination therapy versus 2 months with apalutamide alone (P=0.0008). The company modified the protocol to enroll earlier-stage patients and targets Phase 2 completion by Q4 2027.

Beeline expects Q3 2026 revenue to be second-highest in company history and highest since 2021, with record margins, lower net loss, and lowest adjusted EBITDA loss in 5 years. Cash position expected to increase >50% versus Q2 2026. Company announced pending launch of Home Equity Investment (HEI) product to diversify beyond traditional mortgages and reduce interest-rate dependence. No specific dollar amounts, percentages, or share counts disclosed; results are preliminary pending financial close.

Professional Diversity Network's subsidiary PDN Intelligence ordered one NVIDIA B300-based AI computing system from AMAX Engineering Corporation on October 6, 2026, and has paid 50% of the purchase price with the remainder due before shipment. The system will be deployed at a third-party data center to provide commercial AI compute services. The filing does not disclose the total dollar amount of the purchase price.

60 Degrees Pharmaceuticals announced October 6, 2026 that its randomized Phase IIb/III study of tafenoquine for severe hospitalized babesiosis will conclude enrollment at 30 subjects (vs. originally planned 33). A Data Safety Monitoring Board interim analysis on October 1, 2026 found no safety signals and recommended completing the study as planned. The company will unblind results in January 2027 and seek a pre-sNDA meeting with FDA that same month to discuss regulatory pathway (potential accelerated approval via refractory-disease cases and expanded-access data if the hospital study misses primary endpoint, or regular sNDA if positive). Expanded-access study shows 3 of first 5 enrolled patients achieved molecular cure per NAT testing.

10% owner L1 Capital Pty Ltd (AVR) bought 885K shares (~$6.7M) on the open market (6.5% of holdings). Open-market insider purchase — historically a bullish signal.

Director Troim Tor Olav (BORR) bought 1.5M shares (~$6.2M) on the open market (4.5% of holdings). Open-market insider purchase — historically a bullish signal.

Entravision extended its Station Affiliation Agreement, Marketing and Sales Agreement, and Negotiation Rights Agreement with Univision parties (Network Parties, ULM, and Licensees), all originally expiring December 31, 2026. The extension runs through March 31, 2027, then auto-renews for successive 3-month periods unless either party gives 30 days' notice of non-renewal. Subscriber fees and advertising thresholds from 2026 continue unchanged into subsequent years.

H.B. Fuller completed acquisition of AMS (a UK-based company, financial data as of June 30, 2026). Pro forma combined twelve-month revenue is $3.87B ($3.55B Fuller + $313M AMS), pro forma net income $100M, adjusted EBITDA $713M. Pro forma net leverage 4.2x debt-to-EBITDA and interest coverage 3.3x post-acquisition debt financing.